Regeneron down 3% after appeals court decision in Amgen patent fight
EDT Regeneron (REGN) down 3% after appeals court decision in Amgen (AMGN) patent fightLight Up your Portfolio with Spark:Easily identify ...
Appeals court upholds denial of Regeneron motion for injunction against Amgen
Regeneron Pharmaceuticals (REGN) appealed a decision of the United States District Court for the Northern District of West Virginia denying ...
Struggles Getting Stakeholder Buy-In Slow AI Adoption by In-House Counsel, Users Say
Most organizations have some type of multifunctional committee set up to evaluate generative AI applications. Those ...
Struggles Getting Stakeholder Buy-in Slowing Gen AI Adoption
Most organizations have some type of multi-functional committee set up to evaluate generative AI applications. Those ...